COVID-19 vaccine: Bharat Biotech has recruited 23,000 volunteers for trials, says firm

Suchitra Ella, Joint Managing Director of Bharat Biotech said that the volunteering spirit is a great morale boost for India and the world

Press Trust of India January 03, 2021 11:00:14 IST
COVID-19 vaccine: Bharat Biotech has recruited 23,000 volunteers for trials, says firm

COVAXIN vaccine by Bharath Biotech.

Hyderabad: Bharat Biotech has successfully recruited 23,000 volunteers, and continued progress towards achieving the goal of 26,000 participants for Phase-3 clinical trial of its COVID-19 vaccine Covaxin across multiple sites in India, it said.

The Phase III human clinical trials of Covaxin began mid-November, targeted to be done in 26,000 volunteers and it is the country's first and only Phase III efficacy study for a COVID-19 vaccine, and the largest phase III efficacy trial ever conducted for any vaccine in India, a press release from the vaccine maker said on Saturday night.

Thanking volunteers for their participation in the trials, Suchitra Ella, Joint Managing Director of Bharat Biotech said that the volunteering spirit is a great morale boost for India and the world.

"We thank all the principal investigators, doctors, medical staff and the hospitals for their cooperation and support in taking the phase III trials forward in 26,000 volunteers in India. We continue our progress towards achieving the goal of 26,000 participants for Phase-3 clinical trials of Covaxin," she said.

Covaxin has been evaluated in approximately 1,000 subjects in Phase I and Phase II clinical trials, with promising safety and immunogenicity results, with acceptance in international peer reviewed scientific journals.

It is being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV).

The indigenous, inactivated vaccine is manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) bio-containment facility here, one of its kind in the world

Updated Date:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

AIPSN urges govt to reconsider emergency approval for Covaxin till Phase 3 data is published
India

AIPSN urges govt to reconsider emergency approval for Covaxin till Phase 3 data is published

Either pausing or cancelling approvals is not unheard of, and the CDSCO does have the authority to do so.

Bharat Biotech to pay compensation if Covaxin causes 'severe adverse reaction' in recipients
India

Bharat Biotech to pay compensation if Covaxin causes 'severe adverse reaction' in recipients

The central licensing authority has granted permission for the sale or distribution of Covaxin for restricted use in emergency situations in public interest as an abundant caution, in clinical trial mode

No foreign dignitary at R-Day parade due to COVID-19 crisis; new cases under 20,000 for 7th day
India

No foreign dignitary at R-Day parade due to COVID-19 crisis; new cases under 20,000 for 7th day

In view of the global COVID-19 situation, the Centre has decided not to have a foreign dignitary present at the Republic Day celebrations this year. It will be for the first time in over five decades that there will be no chief guest at the Republic Day parade